Why the FDA is cracking down on compound GLP-1 drugs for weight loss

People who order low-cost versions of the wildly popular weight-loss drugs Wegovy and Zepbound from so-called compounding pharmacies might soon see disruptions in their medication. The U.S. Food and Drug Administration recently announced plans to crack down on the active pharmaceutical ingredients used in glucagonlike peptide 1 (GLP-1) drugs produced at compounding pharmacies, which make…

Read More
Back To Top